Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lymphatic Metastasis 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Gemcitabine 15Cisplatin 15pembrolizumab 9Oxaliplatin 7durvalumab 5Leucovorin 5Fluorouracil 5130-nm albumin-bound paclitaxel 5Platinum 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4Trastuzumab 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Capecitabine 3zanidatamab 2fludarabine 2Paclitaxel 2Nivolumab 2Folfox protocol 2Docetaxel 2Cyclophosphamide 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1pertuzumab 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × peposertib × 1 year × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡